Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Overview | Financials
Company Name Corvus Pharmaceuticals, Inc.
Symbol CRVS
Currency USD
Price 4.52
Market Cap 348,557,992
Dividend Yield 0%
52-week-range 2.47 - 10
Industry Biotechnology
Sector Healthcare
CEO Dr. Richard A. Miller M.D.
Website https://www.corvuspharma.com

An error occurred while fetching data.

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818,

Related Stocks

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

SYRS

0.003 USD

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

16.7 USD

Catalyst Biosciences, Inc. logo

Catalyst Biosciences, Inc.

CBIO

12.3 USD

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

2.19 USD

Venus Concept Inc. logo

Venus Concept Inc.

VERO

2.44 USD

Accelerate Diagnostics, Inc. logo

Accelerate Diagnostics, Inc.

AXDX

0.034 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

2.01 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

2.9 USD

Financials

Numbers are in millions USD

Numbers are in millions USD